Tarsus Pharmaceuticals Inc. (TARS)
NASDAQ: TARSHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
After hours: 73.61 0.00%
TARS stock chart
Technical analysisKey statistics
All statistics- Market cap
- $3.44B
- EPS (TTM)
- -$1.08
- Dividend yield
- None
- 52-week range
- 53.89 – 91.53
- Day range
- 73.30 – 74.68
- Volume / Avg
- 405.14K / 906.66K
- Beta
- —
- Shares outstanding
- 46.79M
- Next earnings
- Nov 3, 2026
52-week range
TARS stock today
Tarsus Pharmaceuticals (TARS) closed at $73.61 on Oct 7, down 0.67% (-$0.50), versus the S&P 500's 0.22% decline. Trading was light, with 405.14K shares changing hands, about 45% of the average daily volume. At this level, TARS sits in the middle of its 52-week range of $53.89 to $91.53: 19.6% below the high, set on Sep 4, 2026 and 36.6% above the low.
TARS is down 10.4% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 7.2%. Tarsus Pharmaceuticals has posted a net loss over the last twelve months (EPS of -$1.08), so its P/E ratio is not meaningful. Tarsus Pharmaceuticals's next earnings report is expected on Nov 3, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Tarsus Pharmaceuticals
Company profileTarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites. It sells its products to specialty pharmacies and distributors, as well as clinics, hospitals, pharmacies, and federal healthcare programs.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Dr. Bobak R. Azamian M.D.
- Headquarters
- Irvine, CA
- Employees
- 370
- IPO year
- 2020
- Website
- tarsusrx.com
Analyst forecast
ForecastConsensus (10 analysts)
strong_buy
Avg. price target
$99.50+35.17%
- Strong buy 1
- Buy 9
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 3, 2026
- EPS estimate
- $-1.49
Tarsus Pharmaceuticals peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| DNLIDenali Therapeutics Inc. | 19.16 | -0.62% | $3.06B | vs TARS |
| RLAYRelay Therapeutics Inc. | 17.95 | -4.22% | $3.93B | vs TARS |
| ADPTAdaptive Biotechnologies Corporation | 26.28 | -2.30% | $4.19B | vs TARS |
| BEAMBeam Therapeutics Inc. | 24.77 | -1.82% | $2.56B | vs TARS |
| RXRXRecursion Pharmaceuticals Inc. Class A | 4.27 | -7.78% | $2.29B | vs TARS |
| ADMAADMA Biologics Inc | 10.14 | -0.39% | $2.27B | vs TARS |
| BCRXBioCryst Pharmaceuticals Inc. | 8.40 | +5.66% | $2.15B | vs TARS |
| ALVOAlvotech | 5.85 | -4.72% | $2.09B | vs TARS |
Indexes, lists and sector
Tarsus Pharmaceuticals stock FAQ
What is Tarsus Pharmaceuticals's stock price today?
TARS last traded at $73.61 as of Oct 7, 4:00 PM EDT, down 0.67% on the day. Prices are delayed at least 15 minutes.
When is Tarsus Pharmaceuticals's next earnings date?
Tarsus Pharmaceuticals is expected to report earnings on Tuesday, November 3, 2026. Analysts expect EPS of $-1.49.
Who is Tarsus Pharmaceuticals's CEO?
Dr. Bobak R. Azamian M.D. is the chief executive officer of Tarsus Pharmaceuticals Inc., which has about 370 employees.
What is the TARS 52-week high?
The 52-week high for TARS is $91.53 and the 52-week low is $53.89. The stock is currently 19.6% below its high.